Billede af showet Therapeutic Momentum

Therapeutic Momentum

Podcast af Therapeutic Momentum

engelsk

Business

Begrænset tilbud

2 måneder kun 19 kr.

Derefter 99 kr. / månedOpsig når som helst.

  • 20 lydbogstimer pr. måned
  • Podcasts kun på Podimo
  • Gratis podcasts
Kom i gang

Læs mere Therapeutic Momentum

The Therapeutic Momentum podcast series illuminates the inspiring personal stories, touchstone moments, and transformational events that fuel the relentless pursuit of life-changing treatments. It reveals the intricate tapestry of experiences that drive people in the biomedical field who share the collective goal of improving patient outcomes. We hope to offer listeners a multifaceted perspective on the diverse talent and backgrounds of people working towards better health and hope for patients.

Alle episoder

8 episoder

episode Kate Haviland: The Bilingual Biotech Leader Behind Blueprint's $9.5B Sanofi Deal cover

Kate Haviland: The Bilingual Biotech Leader Behind Blueprint's $9.5B Sanofi Deal

In this episode I am joined by Kate Haviland, who most recently served as President and CEO of Blueprint Medicines, guiding it from a clinical-stage company through a fully integrated commercial business and ultimately through its roughly $9.5 billion acquisition by Sanofi in 2025. Over a more than twenty-year career spanning Genzyme, PTC Therapeutics, Sarepta, Idera, and Blueprint, Kate has built a reputation for bridging rigorous science with sharp business instincts, equally fluent in the lab and the boardroom. She studied biochemistry and economics at Wesleyan, earned her MBA at Harvard Business School, and today serves as Board Chair of both Fulcrum Therapeutics and GC Therapeutics, as a director at Bicara and Avalyn, and on the board of BIO. This episode was recorded in 2025

16. maj 2026 - 53 min
episode AI + Life Sciences: Why the Future Needs Both Human Brains and Wet Labs cover

AI + Life Sciences: Why the Future Needs Both Human Brains and Wet Labs

In this episode, I speak with Sam Scarpino, Director of AI and Life Sciences at Northeastern University's Institute for Experiential AI and Professor of Public Health and Health Sciences. With a background spanning evolutionary biology, pandemic response during H1N1, and pathogen surveillance at the Rockefeller Foundation, Sam offers a distinctive perspective on artificial intelligence in the life sciences. We discuss the fundamental limitations of AI in biological systems, the irreplaceable role of wet lab experimentation, and how human-AI collaboration can address challenges from rural oncology access to rare disease drug development. Sam also shares his views on why current debates around AGI distract from the urgent work of building responsible AI tools today.

11. apr. 2026 - 57 min
episode Mathai Mammen - Motivated by Math, Medicine & Memories cover

Mathai Mammen - Motivated by Math, Medicine & Memories

Mathai Mammen is a world-renowned innovator in drug discovery, development, and team- and company-building responsible for creating 13 transformational medicines from discovery through commercial launch and more than 25 other potential medicines that have achieved clinical proof-of-concept, many of these practice-changing. Mathai is the CEO, President and Chairman of Cambridge-based Parabilis Medicines, a clinical-stage biopharmaceutical company advancing a new category of peptide therapeutics for people affected by cancer and other severe diseases. Previously Mathai was Executive Vice President of Pharmaceuticals, R&D at Johnson & Johnson, one of the largest R&D organizations in the world. Prior to that Mathai was the leader of much of the research at Merck including Oncology, Immunology and Cardiovascular Disease. He began his career as head of R&D at Theravance, Inc., a company he co-founded out of graduate school based on his work at Harvard University with Dr. George Whitesides, which split to form Theravance Biopharma and Innoviva. Mathai holds an M.D. from the Harvard Medical School and Massachusetts Institute of Technology (HST) and a Ph.D. in chemistry from Harvard University.

20. juli 2025 - 1 h 8 min
En fantastisk app med et enormt stort udvalg af spændende podcasts. Podimo formår virkelig at lave godt indhold, der takler de lidt mere svære emner. At der så også er lydbøger oveni til en billig pris, gør at det er blevet min favorit app.
En fantastisk app med et enormt stort udvalg af spændende podcasts. Podimo formår virkelig at lave godt indhold, der takler de lidt mere svære emner. At der så også er lydbøger oveni til en billig pris, gør at det er blevet min favorit app.
Rigtig god tjeneste med gode eksklusive podcasts og derudover et kæmpe udvalg af podcasts og lydbøger. Kan varmt anbefales, om ikke andet så udelukkende pga Dårligdommerne, Klovn podcast, Hakkedrengene og Han duo 😁 👍
Podimo er blevet uundværlig! Til lange bilture, hverdagen, rengøringen og i det hele taget, når man trænger til lidt adspredelse.

Vælg dit abonnement

Mest populære

Begrænset tilbud

Premium

20 timers lydbøger

  • Podcasts kun på Podimo

  • Ingen reklamer i podcasts fra Podimo

  • Opsig når som helst

2 måneder kun 19 kr.
Derefter 99 kr. / måned

Kom i gang

Premium Plus

100 timers lydbøger

  • Podcasts kun på Podimo

  • Ingen reklamer i podcasts fra Podimo

  • Opsig når som helst

Prøv gratis i 7 dage
Derefter 129 kr. / måned

Prøv gratis

Kun på Podimo

Populære lydbøger

Kom i gang

2 måneder kun 19 kr. Derefter 99 kr. / måned. Opsig når som helst.